ArticlePsychopharmacology2026
Changes of Sonic Hedgehog mediated FAK/ERK pathway proteins in amyotrophic lateral sclerosis model mice.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Therapeutic Potential of Purmorphamine Across Disease Models.Journal of cellular and molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Sonic Hedgehog (SHH) has been shown to be cytoprotective against oxidative stress in a cellular model of amyotrophic lateral sclerosis, and it may support the proliferation and differentiation of endogenous stem cells along the motor neuron lineage and stimulate motor neuron growth and axon formation. However, there is less validation of the role of SHH in a mouse model of amyotrophic lateral sclerosis(ALS). In hSOD1G93A transgenic mice, we found that the expression of SHH, FAK, ERK, p-FAK, and p-ERK was progressively decreased in the spinal cord tissue of hSOD1 mice over time from Western Blot and immunohistochemistry. And compared to the hSOD1 control group, the SHH, FAK, ERK, p-FAK, p-ERK protein levels increased by stimulating SHH with an agonist, while SHH, FAK, p-FAK protein decreased significantly by inhibiting SHH. And the HE staining results of mouse gastrocnemius muscle showed that the agonist group had an increased muscle morphology and more muscle fibers, while the inhibitor group had an atrophied muscle morphology and fewer muscle fibers, than the hSOD1 control group. This confirmed the upstream-downstream relationship among SHH, FAK, and ERK in the spinal cord tissues of hSOD1 mice. Western blot analysis of ERK and p-ERK and immunohistochemical staining revealed declining ERK protein expression in hSOD1 mice, which progressively decreased over time. PUR increased ERK expression, whereas CYC had no significant effect on its reduction. So PUR can activate SHH protein and enhance the function of FAK/ERK. SHH is suggested to play a protective role in the muscle tissue of hSOD1 mice through the FAK/ERK pathway.
Indexed as
Identifiers
40613930What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.